Pharmacokinetic effects and safety of olaparib administered with endocrine therapy: A phase I study in patients with advanced solid tumours.
Plummer, R Verheul, H De Vos, F Leunen, K Molife, L Rolfo, C Grundtvig-Sørensen, P De Grève, J Rottey, S Jerusalem, G
Plummer, R
Verheul, H
De Vos, F
Leunen, K
Molife, L
Rolfo, C
Grundtvig-Sørensen, P
De Grève, J
Rottey, S
Jerusalem, G
Citations
Altmetric:
Abstract
The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer. This phase I study assessed the safety and pharmacokinetic (PK) profiles of olaparib combined with tamoxifen, anastrozole or letrozole in patients with advanced solid tumours.
Description
Date
2018-11
Publisher
Collections
Keywords
Type
Article
Citation
Pharmacokinetic effects and safety of olaparib administered with endocrine therapy: A phase I study in patients with advanced solid tumours. 2018, 35 (11):1945-1964 Adv Ther